VVector Bio offers biomanufacturing services that employ cell culture and fermentation techniques to produce complex biologics for novel therapeutics. The company provides scalable production solutions that comply with regulatory standards, significantly shortening the development timeline for new medicines.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of novel therapeutics, particularly in cell and gene therapy, is often hindered by the complexities and scalability challenges associated with manufacturing complex biologics like viral vectors. Traditional biomanufacturing processes can be time-consuming and costly, delaying the availability of potentially life-saving treatments.
Solution
VVector Bio offers biomanufacturing services specializing in the production of viral vectors, virus-like particles (VLPs), and recombinant proteins to support cell and gene therapy and vaccine development. The company provides end-to-end solutions, including process development, vector design and construction, upstream and downstream processing, purification, and analytical development. VVector Bio leverages cell culture and fermentation techniques in bioreactors, along with advanced plasmid and cell systems, to achieve scalable and reliable manufacturing for pre-clinical studies and beyond. Their expertise in working with various cell lines, such as HEK293, Sf9, and CHO cells, enables them to optimize processes for increased product yields and quality attributes. VVector Bio aims to accelerate the development and commercialization of novel medicines by offering cost-effective and high-quality biomanufacturing services.
Target Audience
VVector Bio serves biotechnology and pharmaceutical companies, as well as research institutions, involved in cell and gene therapy and vaccine development, requiring viral vector manufacturing and process development services for pre-clinical and early-stage clinical studies.
Features
- Viral vector design and construction for AAV, lentivirus, and adenovirus
- Upstream process development, including media evaluation, cell line development, and process optimization strategies using Design of Experiment (DOE)
- Downstream process development, including chromatography (affinity, ion exchange, size exclusion) and filtration (ultrafiltration, diafiltration)
- Analytical development services, including quantification assays (ELISA, ddPCR, protein assay, HPLC), cell-based assays (GTA, TCID50), and identity/purity testing (qPCR, Western blot, SDS-PAGE, sequencing)
- Pre-clinical manufacturing services, including virus seed rescue, production in bioreactors (up to 10L), purification, and final formulation
- Single plasmid technology and high producer cell lines for improved AAV yields
- Capabilities for batch, fed-batch, and perfusion cell culture strategies